193 related articles for article (PubMed ID: 36279564)
1. Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in KRASG12C-mutant Colorectal Cancer.
Khawaja H; Briggs R; Latimer CH; Rassel M; Griffin D; Hanson L; Bardelli A; Di Nicolantonio F; McDade SS; Scott CJ; Lambe S; Maurya M; Lindner AU; Prehn JHM; Sousa J; Winnington C; LaBonte MJ; Ross S; Van Schaeybroeck S
Mol Cancer Ther; 2023 Jan; 22(1):135-149. PubMed ID: 36279564
[TBL] [Abstract][Full Text] [Related]
2. mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1.
Faber AC; Coffee EM; Costa C; Dastur A; Ebi H; Hata AN; Yeo AT; Edelman EJ; Song Y; Tam AT; Boisvert JL; Milano RJ; Roper J; Kodack DP; Jain RK; Corcoran RB; Rivera MN; Ramaswamy S; Hung KE; Benes CH; Engelman JA
Cancer Discov; 2014 Jan; 4(1):42-52. PubMed ID: 24163374
[TBL] [Abstract][Full Text] [Related]
3. The Mutant KRAS Gene Up-regulates BCL-XL Protein via STAT3 to Confer Apoptosis Resistance That Is Reversed by BIM Protein Induction and BCL-XL Antagonism.
Zaanan A; Okamoto K; Kawakami H; Khazaie K; Huang S; Sinicrope FA
J Biol Chem; 2015 Sep; 290(39):23838-49. PubMed ID: 26245900
[TBL] [Abstract][Full Text] [Related]
4. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017
[TBL] [Abstract][Full Text] [Related]
5. Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells.
Okamoto K; Zaanan A; Kawakami H; Huang S; Sinicrope FA
Mol Cancer Res; 2015 Apr; 13(4):659-69. PubMed ID: 25548100
[TBL] [Abstract][Full Text] [Related]
6. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models.
Corcoran RB; Cheng KA; Hata AN; Faber AC; Ebi H; Coffee EM; Greninger P; Brown RD; Godfrey JT; Cohoon TJ; Song Y; Lifshits E; Hung KE; Shioda T; Dias-Santagata D; Singh A; Settleman J; Benes CH; Mino-Kenudson M; Wong KK; Engelman JA
Cancer Cell; 2013 Jan; 23(1):121-8. PubMed ID: 23245996
[TBL] [Abstract][Full Text] [Related]
7. A Novel Combination Treatment Targeting BCL-X
Cho SY; Han JY; Na D; Kang W; Lee A; Kim J; Lee J; Min S; Kang J; Chae J; Kim JI; Park H; Lee WS; Lee C
Mol Cancer Ther; 2017 Oct; 16(10):2178-2190. PubMed ID: 28611106
[TBL] [Abstract][Full Text] [Related]
8. Targeting antioxidant enzymes enhances the therapeutic efficacy of the BCL-X
Oh Y; Jung HR; Min S; Kang J; Jang D; Shin S; Kim J; Lee SE; Sung CO; Lee WS; Lee C; Jeong EM; Cho SY
Cancer Lett; 2021 Jan; 497():123-136. PubMed ID: 33068701
[TBL] [Abstract][Full Text] [Related]
9. BCL-X
Khan S; Wiegand J; Zhang P; Hu W; Thummuri D; Budamagunta V; Hua N; Jin L; Allegra CJ; Kopetz SE; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D
J Hematol Oncol; 2022 Mar; 15(1):23. PubMed ID: 35260176
[TBL] [Abstract][Full Text] [Related]
10. Anti-apoptotic protein BCL-XL as a therapeutic vulnerability in gastric cancer.
Wei Y; Zhang L; Wang C; Li Z; Luo M; Xie G; Yang X; Li M; Ren S; Zhao D; Gao R; Gong JN
Animal Model Exp Med; 2023 Jun; 6(3):245-254. PubMed ID: 37271936
[TBL] [Abstract][Full Text] [Related]
11. Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells.
Risberg K; Redalen KR; Sønstevold L; Bjørnetrø T; Sølvernes J; Ree AH
BMC Cancer; 2016 Jul; 16():531. PubMed ID: 27461218
[TBL] [Abstract][Full Text] [Related]
12. Genomic analysis and selective small molecule inhibition identifies BCL-X(L) as a critical survival factor in a subset of colorectal cancer.
Zhang H; Xue J; Hessler P; Tahir SK; Chen J; Jin S; Souers AJ; Leverson JD; Lam LT
Mol Cancer; 2015 Jul; 14():126. PubMed ID: 26134786
[TBL] [Abstract][Full Text] [Related]
13. The Ewing Family of Tumors Relies on BCL-2 and BCL-X
Heisey DAR; Lochmann TL; Floros KV; Coon CM; Powell KM; Jacob S; Calbert ML; Ghotra MS; Stein GT; Maves YK; Smith SC; Benes CH; Leverson JD; Souers AJ; Boikos SA; Faber AC
Clin Cancer Res; 2019 Mar; 25(5):1664-1675. PubMed ID: 30348635
[TBL] [Abstract][Full Text] [Related]
14. γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells.
Séveno C; Loussouarn D; Bréchet S; Campone M; Juin P; Barillé-Nion S
Breast Cancer Res; 2012 Jun; 14(3):R96. PubMed ID: 22703841
[TBL] [Abstract][Full Text] [Related]
15. Molecular Characterization of Acquired Resistance to KRASG12C-EGFR Inhibition in Colorectal Cancer.
Yaeger R; Mezzadra R; Sinopoli J; Bian Y; Marasco M; Kaplun E; Gao Y; Zhao H; Paula ADC; Zhu Y; Perez AC; Chadalavada K; Tse E; Chowdhry S; Bowker S; Chang Q; Qeriqi B; Weigelt B; Nanjangud GJ; Berger MF; Der-Torossian H; Anderes K; Socci ND; Shia J; Riely GJ; Murciano-Goroff YR; Li BT; Christensen JG; Reis-Filho JS; Solit DB; de Stanchina E; Lowe SW; Rosen N; Misale S
Cancer Discov; 2023 Jan; 13(1):41-55. PubMed ID: 36355783
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of HSP90 by AUY922 Preferentially Kills Mutant KRAS Colon Cancer Cells by Activating Bim through ER Stress.
Wang CY; Guo ST; Wang JY; Liu F; Zhang YY; Yari H; Yan XG; Jin L; Zhang XD; Jiang CC
Mol Cancer Ther; 2016 Mar; 15(3):448-59. PubMed ID: 26832792
[TBL] [Abstract][Full Text] [Related]
17. Beyond cell death - antiapoptotic Bcl-2 proteins regulate migration and invasion of colorectal cancer cells in vitro.
Koehler BC; Scherr AL; Lorenz S; Urbanik T; Kautz N; Elssner C; Welte S; Bermejo JL; Jäger D; Schulze-Bergkamen H
PLoS One; 2013; 8(10):e76446. PubMed ID: 24098503
[TBL] [Abstract][Full Text] [Related]
18. BH3 Mimetic Sensitivity of Colorectal Cancer Cell Lines in Correlation with Molecular Features Identifies Predictors of Response.
Zhang L; Ramesh P; Steinmetz M; Medema JP
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33917026
[TBL] [Abstract][Full Text] [Related]
19. Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancer.
Scherr AL; Mock A; Gdynia G; Schmitt N; Heilig CE; Korell F; Rhadakrishnan P; Hoffmeister P; Metzeler KH; Schulze-Osthoff K; Illert AL; Boerries M; Trojan J; Waidmann O; Falkenhorst J; Siveke J; Jost PJ; Bitzer M; Malek NP; Vecchione L; Jelas I; Brors B; Glimm H; Stenzinger A; Grekova SP; Gehrig T; Schulze-Bergkamen H; Jäger D; Schirmacher P; Heikenwalder M; Goeppert B; Schneider M; Fröhling S; Köhler BC
Cell Death Dis; 2020 Oct; 11(10):875. PubMed ID: 33070156
[TBL] [Abstract][Full Text] [Related]
20. Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in
Nangia V; Siddiqui FM; Caenepeel S; Timonina D; Bilton SJ; Phan N; Gomez-Caraballo M; Archibald HL; Li C; Fraser C; Rigas D; Vajda K; Ferris LA; Lanuti M; Wright CD; Raskin KA; Cahill DP; Shin JH; Keyes C; Sequist LV; Piotrowska Z; Farago AF; Azzoli CG; Gainor JF; Sarosiek KA; Brown SP; Coxon A; Benes CH; Hughes PE; Hata AN
Cancer Discov; 2018 Dec; 8(12):1598-1613. PubMed ID: 30254092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
